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ABSTRACT
Objective: To investigate urine albumin leakage as a
marker of endothelial dysfunction in migraine patients.
Design: A population-based health study.
Participants: 303 patients with migraine, 1009
patients with non-migraine headache and 5287
headache-free controls.
Outcomes: The association between urine albumin-
to-creatine ratio (ACR) and headache status was
investigated in the Nord-Trøndelag Health Study
(HUNT-2). Patients were selected in two strata, based
on either (1) self-reported hypertension/diabetes
(morbid sample) or (2) a random sample. Analyses
were performed using analysis of covariance.
Results: There was no association between headache
status and ACR in the study population (p=0.23, mean
ACR for migraine 1.66, 95% CI 1.31 to 2.01, for non-
migraine headache 1.90, 95% CI 1.71 to 2.09 and for
no headache 1.73, 95% CI 1.64 to 1.81) after relevant
adjustments. Similarly, no association between
headache status and ACR was seen when the analysis
was stratified for morbid and random samples, or for
migraine with and without aura.
Conclusions: We found no evidence of increased
urine albumin leakage in migraine sufferers when
compared with headache-free controls. This could
indicate that systemic endothelial dysfunction is not a
prominent feature of migraine.
INTRODUCTION
Migraine is a common disabling headache
disorder affecting 6–7% of men and 18% of
women.1 It is rated as one of the top 10 most
disabling diseases2 3 and has been estimated
to be the most costly neurological disorder
to society.4 Migraine manifests in headache
attacks lasting 4–72 h characterised by throb-
bing, pulsating and unilateral headache,
often accompanied by nausea, photophobia
and phonophobia.5 In up to a third of the
patients6 these attacks may be accompanied
by additional neurological aura symptoms
separating the disease into migraine with
aura (MA) and migraine without aura
(MO).5
Migraine, in particular MA, has been asso-
ciated with an increased risk of cardiovascular
disease (CVD) including ischaemic stroke,
ischaemic lesions of the brain, myocardial
infarction, angina and cardiovascular death.7–9
While the mechanisms underlying this link
remain unknown, multiple explanations have
been suggested. Shared environmental or
genetic risk factors could be present, changes
in vascular function might contribute to
migraine pathophysiology or the opposite;
migraine pathophysiology could induce
changes in vascular function, or mutual mech-
anistic pathways may exist.10
The vascular endothelium plays an import-
ant role in setting vascular tone, regulating vas-
cular permeability, maintaining thrombotic
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balance and regulating ﬁbrinolytic and inﬂammatory path-
ways. A dysfunctional vascular endothelium is often
observed in CVD.11 Interestingly, abnormal control of sys-
temic vascular tone,12 alterations in systemic arterial struc-
ture and function13 and impaired ability to repair systemic
endothelial injury14 have also been reported in migraine
patients. The increase of systemic vasoactive mediators
during migraine attacks, including the vasoconstrictive
factor ET-1 and the pro-inﬂammatory factor C reactive
protein, suggests an involvement of the endothelium in
migraine headache.15 16 Endothelial dysfunction could
also be implicated in the generation of migraine aura as
ET-1 has been shown to produce cortical spreading
depression, the presumed substrate of migraine aura, in
rats.17 Furthermore, migraine patients with aura have an
increased risk of thrombotic events. It has been reported
raised plasma levels of vWf in migraine patients,18 a factor
that promotes clotting and formation when the endothe-
lium is damaged, further supporting the presence of endo-
thelial dysfunction in migraine. This could explain the
link between migraine and CVD and might elucidate
pathophysiological mechanisms of migraine.
The presence of subclinical increases in urinary
albumin excretion (UAE) has been associated with
impaired endothelium-dependent vasodilation19 and is
believed to reﬂect endothelial dysfunction.20 21 No previ-
ous studies have, however, investigated albumin excre-
tion in migraine patients. The aim of this study was
therefore to compare urine albumin-to-creatine ratio
(ACR), as a measure of UAE, in patients with migraine,
non-migraine headache and headache-free controls.
METHODS
Participants and headache diagnoses
Participants were selected from the second
Nord-Trøndelag Health Study (HUNT 2), a general
health survey conducted in 1995–1997. All inhabitants
aged ≥20 years residing in the county at the time of
screening were invited (n=92 703) and 65 258 patients
(70.4%) participated.22 The population in
Nord-Trøndelag County is ethnically homogenous with
less than 3% non-Caucasians. All participants were mailed
a questionnaire and attended a clinical examination (for
details see ref. 22). The questionnaire included questions
on previous or current CVD, hypertension, diabetes melli-
tus and smoking habits as well as 13 headache questions.
The clinical examination included measurements of
height, weight and blood pressure. When attending the
health examination, participants received a second ques-
tionnaire to complete and return by mail. The 13 head-
ache questions of the questionnaire were designed mainly
to determine whether the individual had headache, the
frequency of headache, and to diagnose migraine accord-
ing to a modiﬁed version of the ICHD migraine cri-
teria.23 24 Participants who answered ‘yes’ to the question
‘Have you suffered from headache during the last
12 months?’ were classiﬁed as headache sufferers. Those
who answered ‘no’ comprised the headache-free control
group. Based on the subsequent 12 headache questions,
headache sufferers were classiﬁed as having migraine if
they fulﬁlled the following three criteria: (1) headache
attacks lasting 4–72 h (less than 4 h was accepted for
those who reported often visual disturbances before head-
ache); (2) headache with at least one of the following
characteristics: pulsating quality, unilateral location, aggra-
vation by physical activity; (3) during headache, at least
one of the following: nausea, photophobia or phonopho-
bia. Those within this group who reported often having
visual disturbance prior to headache were classiﬁed as
having MA. Headache sufferers who did not fulﬁl the cri-
teria for migraine and did not have self-reported
migraine were classiﬁed as having non-migraine head-
ache. Headache diagnoses were mutually exclusive. The
headache diagnoses were validated by clinical interviews
by physicians with long clinical experience in headache
disorders. The positive and negative predictive values of
the questionnaire-based diagnoses were, respectively, 68%
and 76% for non-migraine headache, 87% and 75% for
migraine, and 100% and 91% for MA. A total of 9598
participants were included in a further study in which
they donated three urine samples for the determination
of ACR, originally designed for investigating UAE in
hypertension and diabetes. Participants were included
based on (1) the presence of self-reported diabetes melli-
tus and/or medically treated hypertension (morbid
sample) and (2) a 5% randomly selected sample of the
total population (random sample). Participants who con-
tributed with information regarding both headache status
and ACR were eligible for the present study. Participants
with overt proteinuria, ACR ≥25 mg/mmol in men and
≥35 mg/mmol in women, one participant with migraine
(with aura), 16 participants with non-migraine headache
and 141 participants without headache, were excluded.
In total, 303 participants with migraine, 1009 participants
with non-migraine headache and 5287 headache-free par-
ticipants were included in the study, in which the morbid
sample constituted 3688 medically treated hypertensive
participants, 647 diabetic participants and 413 partici-
pants with both medically treated hypertension and dia-
betes mellitus.
Urine sampling
Participants received a unit with three plastic receptacles
for three ﬁrst morning urine samples, three transport
tubes and one envelope for returning the samples by
mail to the laboratory. Of 11 661 packs handed out,
9598 (82.3%) participants mailed three samples back to
the laboratory.25 Those who failed to return three
samples were excluded. A written instruction describing
how to collect urine, information about the screening
and a questionnaire concerning urinary tract infection
in the previous week, persistent haematuria in the last
year and menstruation at the time of collection was
included. While the most consistent method for deter-
mining UAE is 24 h urine sampling, it has been shown
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that measuring ACR in one or more morning spot urine
samples provides good speciﬁcity and sensitivity.26
Laboratory procedures
Fresh, non-frozen urine samples were analysed at the
Central Laboratory at Levanger Hospital on a Hitachi 91
Autoanalyzer (Hitachi, Mito, Japan). Urine albumin and
creatine levels were determined using an immunoturbi-
metric method (antihuman serum albumin; Dako
Norway, Oslo) and Jaffé method, respectively. The ACR,
measured in mg/mmol, was used as an expression of
UAE.
Consent
Participation in HUNT2 was voluntary and each partici-
pant signed a written consent. All surveys and analyses
were approved by the Norwegian Data Inspectorate and
by the Regional Committee for Medical and Health
Research Ethics.
Statistical analysis
For all analyses we used mean ACR from three delivered
urine samples, measured in mg/mmol. Comparisons of
mean ACR between cases with migraine, non-migraine
headache and headache-free controls in the morbid,
random and combined samples were performed by ana-
lysis of covariance. The confounding effect of potential
confounders, that is, age, sex, body mass index (BMI),
smoking, self-reported diabetes and self-reported antihy-
pertensive medication, in the combined sample was cal-
culated by the formula (mean ACRcrude−mean ACRadj)/
mean ACRcrude, where mean ACRcrude was the mean
ACR in the crude model and mean ACRadj the mean
ACR in the model adjusted for the relevant variable.
Variables with a confounding effect >5% in one or
more headache group were included in the ﬁnal model.
A p value less than 0.05 was used to indicate statistical
signiﬁcance.
RESULTS
Baseline characteristics for the random and morbid
samples are shown in table 1. The morbid sample was
characterised by a higher age and BMI and a lower pro-
portion of smokers as compared with the random
sample. For both samples a higher proportion of women
had headache than men, with the highest percentage of
women found among the migraine participants. The
mean age was lower in the headache groups than in
controls.
Crude analyses indicated an association between ACR
and headache status in the morbid sample (p=0.013,
mean ACR for migraine 1.22, for non-migraine headache
1.95 and for no headache 2.03) and the random sample
(p=0.011, mean ACR for migraine 0.85, for non-migraine
headache 0.96 and for no headache 1.22) (table 2).
However, when adjusting for age and sex this effect disap-
peared (model I). No signiﬁcant associations were
observed between headache status and ACR in the
morbid sample (p=0.11, mean ACR for migraine 1.87,
for non-migraine headache 2.27 and for no headache
1.96) or the random sample (p=0.55, mean ACR for
migraine 1.00, for non-migraine headache 1.07 and for
no headache 1.16) when adjusted for age, sex, self-
reported diabetes and self-reported use of antihyperten-
sive medication (model II).
A similar pattern was observed when morbid and
random samples were combined; crude data indicated
an association between ACR and headache status, but
this effect was explained by differences in age and sex,
table 3. No signiﬁcant associations were observed when
adjusted for age, sex, self-reported diabetes and self-
reported use of antihypertensive medication (p=0.23,
mean ACR for migraine 1.66, for non-migraine head-
ache 1.90 and for no headache 1.73). Mean differences
for ACR in the combined sample (model II) were −0.07
(95% CI −0.43 to 0.30) between migraine participants
and headache-free controls and 0.18 (95% CI −0.04 to
0.39) between non-migraine headache and headache-
free controls. We also examined the association between
Table 1 Clinical profile of the study participants
No headache Non-migraine headache Migraine
Morbid sample (n=4748)
Women (%) 51.7 60.2 69.8
Mean age (SD) 67.0 (11.2) 58.7 (12.9) 51.5 (12.5)
Antihypertensive use (%) 86.9 84.4 83.0
Diabetes (%) 22.5 22.5 20.9
Daily smokers (%) 19.3 24.6 23.1
Mean body mass index (SD) 28.6 (4.5) 29.0 (4.9) 28.7 (4.8)
Random sample (n=1851)
Women (%) 46.8 63.2 75.0
Mean age (SD) 53.9 (16.5) 43.6 (13.7) 39.6 (11.1)
Antihypertensive use (%) 13.1 7.2 7.0
Diabetes (%) 4.1 1.2 0.0
Daily smokers (%) 27.3 33.3 34.8
Mean body mass index (SD) 26.5 (4.0) 26.1 (4.0) 25.8 (3.8)
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Table 2 Albumin-to-creatine ratio (ACR) by headache status and selection criterium
Crude Model I‡ Model II§
Mean ACR (95% CI) N p Value Mean ACR (95% CI) N p Value Mean ACR (95% CI) N p Value
Morbid sample 0.013* 0.13* 0.11*
No headache 2.03 (1.92 to 2.14) 3998 1.96 (1.85 to 2.07) 3998 1.96 (1.85 to 2.06) 3978
Non-migraine headache 1.95 (1.68 to 2.23) 591 0.61† 2.26 (1.97 to 2.54) 591 0.057† 2.27 (1.99 to 2.55) 585 0.044†
Migraine 1.22 (0.68 to 1.75) 159 0.003† 1.85 (1.31 to 2.40) 159 0.70† 1.87 (1.33 to 2.41) 158 0.75†
Random sample 0.011* 0.60* 0.55*
No headache 1.22 (1.11 to 1.32) 1289 1.16 (1.06 to 1.27) 1289 1.16 (1.05 to 1.26) 1285
Non-migraine headache 0.96 (0.77 to 1.14) 418 0.017† 1.08 (0.89 to 1.26) 418 0.44† 1.07 (0.89 to 1.26) 417 0.44†
Migraine 0.85 (0.53 to 1.16) 144 0.028† 1.02 (0.70 to 1.34) 144 0.41† 1.00 (0.68 to 1.31) 143 0.35†
*p Value for overall effect of headache groups.
†p Values are for comparison against no headache group within the same selection criterium.
‡Model I: adjusted for age and sex.
§Model II: adjusted for age, sex, self-reported diabetes and self-reported use of antihypertensive medication.
Table 3 Albumin-to-creatine ratio (ACR) by headache status in combined sample
Crude Model I‡ Model II§
Mean ACR (95% CI) N p Value Mean ACR (95% CI) N p Value Mean ACR (95% CI) N p Value
<0.001* 0.29* 0.23*
No headache 1.83 (1.75 to 1.92) 5287 1.73 (1.65 to 1.81) 5287 1.73 (1.64 to 1.81) 5263
Non-migraine headache 1.54 (1.35 to 1.73) 1009 0.007† 1.89 (1.69 to 2.09) 1009 0.15 1.90 (1.71 to 2.09) 1002 0.11†
Migraine 1.04 (0.69 to 1.39) 303 <0.001† 1.67 (1.31 to 2.03) 303 0.74 1.66 (1.31 to 2.01) 301 0.72†
*p Value for overall effect of headache groups.
†p Values are for comparison against no headache group.
‡Model I: adjusted for age and sex.
§Model II: adjusted for age, sex, self-reported diabetes and self-reported use of antihypertensive medication.
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headache status and ACR after stratiﬁcation of migraine
into its two subtypes MA and MO. In the adjusted
model, no differences in ACR scores were found
between migraine subtype and controls (p=0.68, mean
ACR for MA 1.36, for MO 1.73 and for no headache
1.73; table 4). There was no interaction between head-
ache status and self-reported diabetes, or between head-
ache status and self-reported use of antihypertensive
medication on ACR. Since the measurement ACR was
positively skewed, we repeated the analyses after square
root transformation, which provided similar results. To
ease interpretation only non-transformed results are
presented.
DISCUSSION
The present study did not ﬁnd an association between
headache status and ACR, indicating the absence of
large differences in urine albumin leakage between
migraine participants or other headache sufferers and
headache-free controls. The mechanisms linking
migraine and CVD are likely complex, but dysregulation
of vascular endothelium as expressed by albumin
leakage is not supported by the present data to be a
major factor.
The study includes a relatively large sample size,
objective measurements of UAE, analyses based on fresh
urine samples and the use of validated headache diagno-
ses. Furthermore, the design of the study allowed us to
evaluate the association between headache status and
UAE in a random sample as well as a morbid sample,
which included a high proportion of participants with
hypertension and diabetes types I and II, well-known risk
factors for increased UAE.27–29 A limitation of the study
is, however, that hypertension and diabetes information
was based on self-report. Data on participants’ migraine
status (ictal or interictal phase) during urine sampling
was not available and it cannot be excluded that there
may be a difference in urine albumin leakage during
and outside a migraine attack. In addition, the sample
size might be too low to detect ACR differences among
migraine subtypes. In particular, there was a limited
number of participants having MA in this study.
A high level of urine ACR, most likely representing
excessive glomerular capillary leakage of albumin,19 is a
risk marker for cardiovascular morbidity and mortality30
and is believed to reﬂect endothelial dysfunction.19 21
Increased UAE has been associated with impaired
endothelium-dependent vasodilatation,19 impaired per-
ipheral vasoreactivity to endothelial agonists31 as well as
with circulating biomarkers of endothelial dysfunction.32
Abnormal ACR levels in urine have also been reported
in inﬂammatory, non-cardiovascular conditions such as
rheumatoid arthritis, inﬂammatory bowel syndrome and
surgery, which has been hypothesised to be a result of
circulating inﬂammatory molecules damaging parenchy-
mal functions of the kidneys.20 Interestingly, ACR levels
even within the normal range have been associated with
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an increased rate of kidney disease, CVD and mortal-
ity.33–35 As UAE is a biological continuum, we used con-
tinuous ACR values in the present study rather than
applying microalbuminuria commonly deﬁned as ACR
≥2.5 mg/mmol. The mean ACR levels in the morbid
group of the present study were twice as high as for the
randomly chosen sample, which is explained by the pres-
ence of hypertension and diabetes. In the random
sample, however, ACR was generally low for all headache
and headache-free groups.
The unadjusted analysis indicated an association
between ACR and headache status in the morbid,
random and combined samples. However, when adjust-
ing for age and sex the association disappeared, suggest-
ing these variables to be the major contributing factors
for differences in ACR in the present study. Given the
fact that women have less muscular mass and lower cre-
atine excretion than men, and that creatine excretion
decreases with age,25 a confounding effect of age and
sex on ACR was not unexpected.
Contrary to our hypothesis we did not ﬁnd urine
albumin leakage to be more prominent among migraine
sufferers than among headache-free participants. If
endothelial dysfunction with albumin leakage was a
feature of migraine, we would expect elevated ACR
levels among migraine participants, and highest among
MA. Although we could not ﬁnd an association between
ACR and migraine status, there was a non-signiﬁcant ten-
dency in the opposite direction; participants with MA
had the lowest ACR levels. While many previous studies
favour the presence of endothelial dysfunction in
migraine patients, some studies argue against it. In fact,
systemic endothelium-dependent vasodilation, nitric
oxide levels and stimulated t-PA levels have been found
similarly expressed in migraine participants and healthy
controls.36–38 Furthermore, it was recently suggested that
extracranial dilatation may not be relevant for migraine
pain during attacks.39
In summary, in this ﬁrst study examining albumin
leakage in migraine sufferers, we did not ﬁnd urine
albumin leakage to be more prominent among migraine
participants than among headache-free participants,
which could indicate that systemic endothelial dysfunc-
tion is not a prominent feature of migraine.
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